Royalty Pharma Due for Wall Street Appraisal After 70% Surge
A bottle of Truvada is at at a pharmacy.
Photographer: Justin Sullivan/Getty Images North AmericaThis article is for subscribers only.
Royalty Pharma Plc could get another boost on Monday when analysts weigh in for the first time following a 70% rally since last month’s trading debut.
Underwriters of the hedge-fund darling’s initial public offering will be eligible to start coverage next week, including JPMorgan, Morgan Stanley, Bank of America, Goldman Sachs, Citigroup and UBS. Banks that help bring a company’s listing to market often have favorable reviews.